Mirvetuximab soravtansine

MIRASOL, Study 0416

Mirvetuximab soravtansine MIRASOL, Study 0416

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

?

QoL data pending

Serious and disabling adverse effects

Other adjustments

Mirvetuximab soravtansine MIRASOL, Study 0416

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

3

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
Therapeutic Indication: Mirvetuximab soravtansine for adult patients with FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1-3 prior systemic treatment regimens
Experimental Arm: Mirvetuximab soravtansine
Control Arm: Paclitaxel, pegylated liposomal doxorubicin, or topotecan. (Investigator's choice of chemotherapy)